Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Express Scripts
AstraZeneca
Moodys
Baxter

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,227,295

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,227,295
Title:Selective histone deactylase 6 inhibitors
Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
Inventor(s): Sotomayor; Eduardo M. (Tampa, FL), Bergman; Joel A. (Chicago, IL), Kozikowski; Alan P. (Chicago, IL), Villagra; Alejandro V. (Tampa, FL), Woan; Karrune V. (Gainesville, FL)
Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) Board of Trustees of The University of Illinois (Urbana, IL)
Application Number:15/695,435
Patent Claims:1. A method of treating melanoma in a subject, comprising: administering to the subject a therapeutically effective amount of a histone deacetylase inhibitor having a structure represented by Formula I: ##STR00037## wherein A is aryl, heteroaryl, or C.sub.1-C.sub.8 alkyl, any of which is optionally substituted with one or more groups chosen from acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.1 is hydrogen and R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.8 haloalkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, C.sub.1-C.sub.3 alkylaryl, aryl, C.sub.1-C.sub.3 alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, C.sub.1-C.sub.4 alkyl, or are joined such that together they form an alkylene bridge comprising 4 or 5 atoms so that a 5 or 6-membered ring is formed with the nitrogen; or a pharmaceutically acceptable salt or hydrate thereof.

2. The method of claim 1, wherein the inhibitor is a histone deacetylase 6 inhibitor.

3. The method of claim 1, wherein the inhibitor is Tubstatin A.

4. The method of claim 1, wherein the inhibitor is administered with one or more of ipilimumab, revlimid, velcade, vemurafenib, ST-3-06, ST-2-92, Tubstatin A, Tubacin.

5. The method of claim 1, wherein the inhibitor is combined with a STAT3 inhibitor.

6. A method of treating melanoma in a subject comprising administering a therapeutically effective amount of a cancer immunotherapy agent and a histone deacetylase inhibitor having a structure represented by Formula I: ##STR00038## wherein A is aryl, heteroaryl, or C.sub.1-C.sub.8 alkyl, any of which is optionally substituted with one or more groups chosen from acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.1 is hydrogen and R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.8 haloalkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, C.sub.1-C.sub.3 alkylaryl, aryl, C.sub.1-C.sub.3 alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, C.sub.1-C.sub.4 alkyl, or are joined such that together they form an alkylene bridge comprising 4 or 5 atoms so that a 5 or 6-membered ring is formed with the nitrogen; or a pharmaceutically acceptable salt or hydrate thereof.

7. The method of claim 6, wherein the immunotherapy agent is an antibody selected from anti-CLTA-4, anti-PD-1, or anti-PDL1.

8. The method of claim 6, wherein the immunotherapy agent is an IL-10 inhibitor.

9. A method of treating melanoma in a subject, comprising administering an effective amount of a toll like receptor agonist and a histone deactylase inhibitor having a structure represented by Formula I: ##STR00039## wherein A is aryl, heteroaryl, or C.sub.1-C.sub.8 alkyl, any of which is optionally substituted with one or more groups chosen from acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.1 is hydrogen and R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, C.sub.1-C.sub.8 alkynyl, C.sub.1-C.sub.8 haloalkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, C.sub.1-C.sub.3 alkylaryl, aryl, C.sub.1-C.sub.3 alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, C.sub.1-C.sub.4 alkyl, or are joined such that together they form an alkylene bridge comprising 4 or 5 atoms so that a 5 or 6-membered ring is formed with the nitrogen; or a pharmaceutically acceptable salt or hydrate thereof.

10. The method of claim 1, wherein A is phenyl, pyridyl, oxazolidyl, pyrimidyl, pyrimidinyl, or 1H-indazolyl, optionally substituted with C.sub.1-C.sub.5 alkyl, amino, alkoxy, alkylhydroxy, halo, hydroxy, or thiol.

11. The method of claim 1, wherein A is pyrimidinyl or 1H-indazolyl substituted with C.sub.1-C.sub.5 alkyl, C.sub.1-C.sub.4 alkoxyl, or halo.

12. The method of claim 1, wherein R.sup.2 is C.sub.1-C.sub.8 alkyl, C.sub.5-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 heterocycloalkyl, aryl, or heteroaryl, any of which is optionally substituted with C.sub.1-C.sub.5 alkyl, amino, --NR.sup.6R.sup.7, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkylhydroxy, carbonyl, hydroxy, thiol, or cyano.

13. The method of claim 1, wherein R.sup.2 is C.sub.1-C.sub.5 alkyl, or C.sub.1-C.sub.5 alkyl substituted with a methoxy, amino, --NR.sup.6R.sup.7, alkylhydroxy, carbonyl, hydroxy, cyano.

14. The method of claim 1, wherein R.sup.2 is C.sub.1-C.sub.4 alkyl.

15. The method of claim 1, wherein the structure according to Formula I is chosen from: ##STR00040##

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
Baxter
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.